Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP624691.RAYj551fnwTF9T-qkVtK5FyOEw-W_dnyySwZPtjjB9ncw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP624691.RAYj551fnwTF9T-qkVtK5FyOEw-W_dnyySwZPtjjB9ncw130_assertion type Assertion NP624691.RAYj551fnwTF9T-qkVtK5FyOEw-W_dnyySwZPtjjB9ncw130_head.
- NP624691.RAYj551fnwTF9T-qkVtK5FyOEw-W_dnyySwZPtjjB9ncw130_assertion description "[Subsets of non-small cell lung cancer (NSCLC) patients who carry activating somatic mutations of the epidermal growth factor receptor (EGFR) have demonstrated an increased probability of obtaining objective responses to the receptor tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624691.RAYj551fnwTF9T-qkVtK5FyOEw-W_dnyySwZPtjjB9ncw130_provenance.
- NP624691.RAYj551fnwTF9T-qkVtK5FyOEw-W_dnyySwZPtjjB9ncw130_assertion evidence source_evidence_literature NP624691.RAYj551fnwTF9T-qkVtK5FyOEw-W_dnyySwZPtjjB9ncw130_provenance.
- NP624691.RAYj551fnwTF9T-qkVtK5FyOEw-W_dnyySwZPtjjB9ncw130_assertion SIO_000772 17695517 NP624691.RAYj551fnwTF9T-qkVtK5FyOEw-W_dnyySwZPtjjB9ncw130_provenance.
- NP624691.RAYj551fnwTF9T-qkVtK5FyOEw-W_dnyySwZPtjjB9ncw130_assertion wasDerivedFrom befree-2016 NP624691.RAYj551fnwTF9T-qkVtK5FyOEw-W_dnyySwZPtjjB9ncw130_provenance.
- NP624691.RAYj551fnwTF9T-qkVtK5FyOEw-W_dnyySwZPtjjB9ncw130_assertion wasGeneratedBy ECO_0000203 NP624691.RAYj551fnwTF9T-qkVtK5FyOEw-W_dnyySwZPtjjB9ncw130_provenance.